The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis.
Mitchell Joseph LycettRodney A LeaVicki E MaltbyMyintzu MinJeannette Lechner-ScottPublished in: Multiple sclerosis journal - experimental, translational and clinical (2023)
Cladribine therapy for RRMS was not associated with immunoglobulin subset deficiencies. This is contrasted to ocrelizumab and natalizumab which demonstrate significant reductions in both IgG and IgM levels.